Share

    


Home / Search Results

Search Results

Search Publications

Search Again?

Filter By Content Type

Filter By Topic

Understanding the Impact of Disparities and Social Determinants of Health on Cancer Care Alti Rahman, MHA/MBA, CSSBB Practice Administrator Susan Sabo-Wagner, MSN, RN, OCN Executive Director of Clinical Strategy Oncology Consultants Disclosure of Conflicts of Interest • Alti Rahman, MHA/MBA, CSSBB, has no relevant financial relationships to disclose. • Susan …
Tune-in as our expert discusses how and when to screen patients, and then connect them to available resources to better support patients’ financial needs.
Ongoing clinical trials ER+ Changes in the Treatment Landscape of HER2 Positive Breast Cancer Virginia Kaklamani, MD DSc Professor of Medicine Leader, Breast Oncology Program Disclosures • Honoraria from: Daichi, Astrazeneka, Genentech, Gilead, Novartis, Pfizer, Seagen, Lilly, Genomic Health • Grant/Research funding from: EISAI Response to Chemo in Locally …
The Impact of COVID-19 Pandemic on Colorectal Cancer Screening and Treatment: Preliminary Results of a Community Hospital Based Study Ahmed Abdelhakeem, MD Baptist Hospitals of Southeast Texas, Beaumont, TX Collaborators ▪ Muhammad Siddiqi, MD ▪ Nigil Thaimuriyil, DO ▪ Chelsey Peters. ▪ Samantha Blevins. ▪ Tahir Naqvi, MD. Disclosure ▪ The authors …
1801 Research Boulevard, Suite 400 • Rockville, MD 20850 • T: 301.984.9496 • F: 301.770.1949 • www.accc-cancer.org October 11, 2022 The Honorable Robert M. Califf, M.D. Commissioner of Food and Drugs U.S. Food and Drug Administration 10903 New Hampshire Avenue Silver Spring, MD 20993 RE: Inspections of Manufacturing Facilities Dear Commissioner …
1801 Research Boulevard, Suite 400 • Rockville, MD 20850 • T: 301.984.9496 • F: 301.770.1949 • www.accc-cancer.org October 11, 2022 The Honorable Robert M. Califf, M.D. Commissioner of Food and Drugs U.S. Food and Drug Administration 10903 New Hampshire Avenue Silver Spring, MD 20993 RE: Inspections of Manufacturing Facilities Dear Commissioner …
The evolving role of surgery for renal cell carcinoma Surena F. Matin, MD Professor, Department of Urology Medical Director, MINTOS program Minimally Invasive New Technology in Oncologic Surgery Twitter: @SurenaMatinMD The evolving role of surgery for renal cell carcinoma Disclosure of Conflicts of Interests Surena F. Matin, MD, has the following financial relationships to …
Advocating for Medication Access: How Practices Can Navigate White Bagging Mandates and Drug Authorization Restrictions Jorge J. Garcia, PharmD, MS, MHA, MBA, FACHE Assistant Vice President Pharmacy Services Baptist Health South Florida Disclosure of Conflicts of Interest: Jorge J. Garcia, PharmD, MS, MHA, MBA, FACHE, has the following financial relationships …
1801 Research Boulevard, Suite 400 • Rockville, MD 20850 • T: 301.984.9496 • F: 301.770.1949 • www.accc-cancer.org October 18, 2022 The Honorable Charles Schumer Majority Leader U.S. Senate Washington, DC 20510 The Honorable Nancy Pelosi Speaker U.S. House of Representatives Washington, DC 20515 The Honorable Mitch McConnell Minority Leader …
ACCC sent a letter to House and Senate leaders this week, encouraging Congress to take action before the end of this year to mitigate significant Medicare payment cuts and improve patient access to high quality, efficient, and equitable cancer care. Without congressional intervention, significant reductions to Medicare payment will take effect in January 2023, including the proposed 4.42% reduction …
In recognition of Pharmacy Technician Day today (October 18), ACCCBuzz spoke with Danielle Duy, CPhT, to learn more about her role on the multidisciplinary cancer care team.
Learn more about how this health system is gleaning new insights into clinical workforce needs to optimize future staffing and scheduling decisions.
Awards recognize significant contributions to oncology care ROCKVILLE, MD – The Association of Community Cancer Centers (ACCC) today announced the 2022 Annual Award recipients at the ACCC 39th Annual National Oncology Conference. Oncology leaders across the country are convening this week at the association’s national conference to discuss innovation and ways to create positive change among …
In this episode, Dr. Noel breaks down how to build trust and earn the respect of under-represented patient populations in the community.
Healthcare—especially oncology—is rife with competing demands that make it particularly challenging to engage oncology staff in innovation. #ACCCNOC keynote speaker Julie Holmes shares her principles for innovating in healthcare through “little big bangs” (or micro-innovations).
Created to address burnout and improve retention rates, Medstar's Regional Staff Support Program provides staff with an opportunity to participate in monthly employee celebrations, encourages peer-to-peer recognition, and enhances communication among associates.
Accelerated Approvals Reconsidered None Changes in Dosing/Administration None Changes in Labeled Indications Imfinzi® (durvalumab) – AstraZeneca’s PD-L1 inhibitor was newly approved for use, in combination with gemcitabine and cisplatin, as treatment for adult patients with locally advanced or metastatic biliary tract cancer (BTC). The expansion beyond lung cancer—where the IO agent …
Accelerated Approvals Reconsidered None Changes in Dosing/Administration None Changes in Labeled Indications Imfinzi® (durvalumab) – AstraZeneca’s PD-L1 inhibitor was newly approved for use, in combination with gemcitabine and cisplatin, as treatment for adult patients with locally advanced or metastatic biliary tract cancer (BTC). The expansion beyond lung cancer—where the IO agent …
Accelerated Approvals Reconsidered None Changes in Dosing/Administration None Changes in Labeled Indications Imfinzi® (durvalumab) – AstraZeneca’s PD-L1 inhibitor was newly approved for use, in combination with gemcitabine and cisplatin, as treatment for adult patients with locally advanced or metastatic biliary tract cancer (BTC). The expansion beyond lung cancer—where the IO agent …